




RealRate

PHARMACEUTICAL 2022

Gain Therapeutics Inc
Rank 125 of 471

GAIN
THERAPEUTICS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Gain Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Gain Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Gain Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 360%, being 85% points above the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	37,722	Assets	38,985
Cost of Goods Sold	0	Liabilities	4,168
Intangible Assets	0	Expenses	13,995
Liabilities, Current	2,553	Revenues	165
Liabilities, Non-Current	1,615	Stockholders Equity	34,818
Other Assets	1,157	Net Income	-13,891
Other Compr. Net Income	0	Comprehensive Net Income	-13,891
Other Expenses	4.0	BaseVar	28,687
Other Liabilities	0	ECR before LimitedLiability	287%
Other Net Income	-60	Economic Capital Ratio	360%
Other Revenues	165		
Property and Equipment	106		
Research and Development	7,164		
Selling, General and Administrative Expense	6,827		